Drugmaker will Contribute meds for USA push to end HIV epidemic

PrEP Impact trial Man holding a pill used for Pre Exposure Prophylaxis to prevent HIV infection

They have produced the costliest HIV drug which will protect the people from getting infected. President Donald Trump said in a celebratory tweet.

Gilead's release also reconfirms plans to transition PrEP patients to a drug that has fewer side effects, Descovy, which would conveniently maintain the company's lucrative patent over PrEP provisions for years to come.

Gilead will donate its Truvada prevention pill until a second-generation version becomes available.

The agreement between the U.S. Department of Health and Human Services and Gilead will last until at least December 31, 2025 and possibly through December 31, 2030, and will provide medication to treat individuals who are at risk for HIV and who are uninsured. Azar explained the Truvada donation would allow Americans, who would normally not be able to afford or even access the drug, to receive HIV treatment.

Following Gilead's announcement, HHS Sec.

The Trump administration has set a objective of ending the HIV outbreak in the US over a decade.

Gilead Sciences will donate emtricitabine/tenofovir disoproxil fumarate (Truvada), the only drug approved to prevent infection with HIV, to the United States in order to supply 200,000 patients annually for up to 11 years.

The U.S. government has agreed to cover the costs of distributing Truvada to Americans all over the country. In 2017, the rural parts of seven Southern States had around 20,000 new HIV diagnoses which were higher than the other parts of America.

Carl Schmid, AIDS Institute deputy executive director, welcomed the donation from Gilead, stating that it would free up federal government spending that would otherwise be used on getting medication of uninsured people.

HIV is the virus that causes AIDS. However, the House Appropriations Committee has approved almost $500 million in spending for disease treatment and prevention earlier this week.



Other news